Assenagon Asset Management
FDMT icon

Assenagon Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Assenagon Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Hold
83,333
– – ﹤0.01% 958
2026
Q1 		$776K Sell
83,333
-212,866
-72% -$1.85M ﹤0.01% 938
2025
Q4 		$2.22M Sell
296,199
-367,458
-55% -$3.73M ﹤0.01% 809
2025
Q3 		$5.77M Buy
663,657
+14,832
+2% +$88.6K 0.01% 592
2025
Q2 		$2.41M Sell
648,825
-2,131
-0.3% -$7.49K ﹤0.01% 742
2025
Q1 		$2.1M Sell
650,956
-2,574
-0.4% -$12.1K ﹤0.01% 749
2024
Q4 		$3.64M Sell
653,530
-889,884
-58% -$6.98M 0.01% 768
2024
Q3 		$16.7M Buy
1,543,414
+1,087,147
+238% +$18M 0.03% 391
2024
Q2 		$9.58M Buy
456,267
+25,711
+6% +$645K 0.02% 439
2024
Q1 		$13.7M Buy
+430,556
New +$11M 0.03% 355

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Assenagon Asset Management's FDMT Position: Q2 2026 in Review

Assenagon Asset Management held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 83,333 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #958.

Assenagon Asset Management first reported a position in FDMT in Q1 2024 and has held it in 10 quarters since. The position peaked at $16.7M in Q3 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Assenagon Asset Management held 83,333 shares of 4D Molecular Therapeutics worth $1.11M as of Q2 2026.
  • Assenagon Asset Management left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #958 holding.
  • Assenagon Asset Management first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Assenagon Asset Management's 4D Molecular Therapeutics position peaked at $16.7M in Q3 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.